[go: up one dir, main page]

CO6440558A2 - PHARMACEUTICAL COMPOSITIONS OF PRODUCT PERFORMANCE AND COMPLIANCE OF THE PATIENT SUPERIOR - Google Patents

PHARMACEUTICAL COMPOSITIONS OF PRODUCT PERFORMANCE AND COMPLIANCE OF THE PATIENT SUPERIOR

Info

Publication number
CO6440558A2
CO6440558A2 CO11082167A CO11082167A CO6440558A2 CO 6440558 A2 CO6440558 A2 CO 6440558A2 CO 11082167 A CO11082167 A CO 11082167A CO 11082167 A CO11082167 A CO 11082167A CO 6440558 A2 CO6440558 A2 CO 6440558A2
Authority
CO
Colombia
Prior art keywords
compliance
pharmaceutical compositions
product performance
patient superior
superior
Prior art date
Application number
CO11082167A
Other languages
Spanish (es)
Inventor
Ashish Chatterji
Dipen Desai
Harpreet K Sandhu
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO6440558A2 publication Critical patent/CO6440558A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona nuevasformulaciones de (2R, 3R, 4R, 5R)-5-(4-amino-2-oxo-2H-pirimidin-1-il)-4-fluoro-2-isobutiriloximetil-4-metil-tetrahidrofurán-3-iI éster de ácido isobutírico e hidroxipropilcelulosaque proporcionan una elevada densidad aparente y untamaño de gránulo reducido más adecuados para unacompresión y flujo mejorados, buena compresión, y perfilesde disolución rápida.The present invention provides new formulations of (2R, 3R, 4R, 5R) -5- (4-amino-2-oxo-2H-pyrimidin-1-yl) -4-fluoro-2-isobutyryloxymethyl-4-methyl-tetrahydrofuran- 3-iI ester of isobutyric acid and hydroxypropyl cellulose which provide high bulk density and reduced granule size more suitable for improved compression and flow, good compression, and fast dissolution profiles.

CO11082167A 2009-01-21 2011-06-30 PHARMACEUTICAL COMPOSITIONS OF PRODUCT PERFORMANCE AND COMPLIANCE OF THE PATIENT SUPERIOR CO6440558A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14599909P 2009-01-21 2009-01-21

Publications (1)

Publication Number Publication Date
CO6440558A2 true CO6440558A2 (en) 2012-05-15

Family

ID=42026386

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11082167A CO6440558A2 (en) 2009-01-21 2011-06-30 PHARMACEUTICAL COMPOSITIONS OF PRODUCT PERFORMANCE AND COMPLIANCE OF THE PATIENT SUPERIOR

Country Status (28)

Country Link
US (1) US8222230B2 (en)
EP (1) EP2389164B1 (en)
JP (1) JP5415561B2 (en)
KR (1) KR101331723B1 (en)
CN (1) CN102292075B (en)
AR (1) AR075037A1 (en)
AU (1) AU2010206224B2 (en)
BR (1) BRPI1006924A2 (en)
CA (1) CA2748895C (en)
CL (1) CL2011001764A1 (en)
CO (1) CO6440558A2 (en)
DK (1) DK2389164T3 (en)
EC (1) ECSP11011191A (en)
ES (1) ES2513415T3 (en)
HK (1) HK1164742A1 (en)
IL (1) IL213804A0 (en)
MA (1) MA32969B1 (en)
MX (1) MX2011007771A (en)
NZ (1) NZ593795A (en)
PE (1) PE20120020A1 (en)
PL (1) PL2389164T3 (en)
RU (1) RU2489153C2 (en)
SG (1) SG173001A1 (en)
SI (1) SI2389164T1 (en)
TW (1) TWI414295B (en)
UA (1) UA100937C2 (en)
WO (1) WO2010084041A2 (en)
ZA (1) ZA201104882B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062691A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treating hcv infections
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
DE102013215831A1 (en) * 2013-08-09 2015-02-12 Beiersdorf Ag Gel-shaped, alcoholic sunscreen
JP6697402B2 (en) * 2015-01-30 2020-05-20 協和発酵バイオ株式会社 Highly functional tablet-containing tablet and method for producing the same
US10588978B2 (en) * 2016-02-19 2020-03-17 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing imidazoline derivative
JP6323846B2 (en) * 2016-04-07 2018-05-16 塩野義製薬株式会社 Abuse prevention formulation containing opioid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032005A3 (en) * 2001-01-22 2004-04-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
JP4408340B2 (en) * 2002-03-22 2010-02-03 武田薬品工業株式会社 Fast disintegrating solid preparation
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
EP1900368B1 (en) * 2005-06-22 2011-05-11 Takeda Pharmaceutical Company Limited Tablet containing hardly soluble active ingredient
JP2008230967A (en) * 2005-06-23 2008-10-02 Kowa Co Pharmaceutical composition
EP1957510A1 (en) * 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides
CA2631498A1 (en) 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation

Also Published As

Publication number Publication date
KR101331723B1 (en) 2013-11-26
TW201031410A (en) 2010-09-01
EP2389164B1 (en) 2014-08-13
HK1164742A1 (en) 2012-09-28
IL213804A0 (en) 2011-07-31
SG173001A1 (en) 2011-08-29
AU2010206224B2 (en) 2012-12-13
JP2012515739A (en) 2012-07-12
BRPI1006924A2 (en) 2016-02-16
ECSP11011191A (en) 2011-10-31
US20100184716A1 (en) 2010-07-22
RU2489153C2 (en) 2013-08-10
CA2748895C (en) 2014-05-13
DK2389164T3 (en) 2014-09-15
CA2748895A1 (en) 2010-07-29
AR075037A1 (en) 2011-03-02
PL2389164T3 (en) 2015-01-30
KR20110117683A (en) 2011-10-27
MA32969B1 (en) 2012-01-02
EP2389164A2 (en) 2011-11-30
PE20120020A1 (en) 2012-02-02
MX2011007771A (en) 2011-08-12
JP5415561B2 (en) 2014-02-12
WO2010084041A2 (en) 2010-07-29
ZA201104882B (en) 2012-03-28
CN102292075B (en) 2013-04-17
WO2010084041A3 (en) 2011-08-18
SI2389164T1 (en) 2014-12-31
TWI414295B (en) 2013-11-11
CL2011001764A1 (en) 2012-01-20
CN102292075A (en) 2011-12-21
AU2010206224A1 (en) 2011-08-25
ES2513415T3 (en) 2014-10-27
RU2011134713A (en) 2013-03-10
NZ593795A (en) 2013-02-22
UA100937C2 (en) 2013-02-11
US8222230B2 (en) 2012-07-17

Similar Documents

Publication Publication Date Title
CO6440558A2 (en) PHARMACEUTICAL COMPOSITIONS OF PRODUCT PERFORMANCE AND COMPLIANCE OF THE PATIENT SUPERIOR
CY1118454T1 (en) ORIGINAL PYROLLI INHIBITORS OF S-NITROZOGLUTATHYONE PRODUCTION AS THERAPEUTIC AGENTS
AR084473A1 (en) PHARMACEUTICAL COMPOSITIONS OF (R) 1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-IL) -N- (1- (2,3-DIHYDROXIPROPIL) -6-FLUORO-2- (1 -HYDROXI-2-METHYLPROPAN-2-IL) -1H-INDOL-5-IL) CYCLOPROPANECARBOXAMIDE
MY161088A (en) Agonists of gpr40
CL2008003827A1 (en) Composition for orally disintegrating tablets comprising at least one drug (temazepam), 0.5-3% of a binder polymer for odt, a sugar alcohol and / or saccharide, and a disintegrant; method to prepare it; Useful to treat a disease or condition such as a sleep disorder in patients with dysphagia.
EA201070421A1 (en) MICRORIPONIC ACID
WO2009120919A3 (en) Fenofibrate dosage forms
EP2535058A3 (en) Stabilization of vaccines by lyophilization
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
IN2012DN01435A (en)
MX373230B (en) PHARMACEUTICAL COMPOSITION AND ITS ADMINISTRATION.
MX2012003555A (en) Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same.
CL2011002432A1 (en) Composition comprising at least one digestive enzyme and at least one carrier, wherein the carrier comprises microcrystalline cellulose having a particle size greater than 100 um; a dosage form; the container that contains it; a process to prepare the composition; and its uses
CL2013002241A1 (en) Compounds derived from (4,4'-biphenylbis (1h-imidazol-4,2-diyl) -2,1-pyrrolidindiyl ((1s) -1 - ((2r, 6r) -2,4-dimethyltetrahydro-2h-pyran -4-yl) -2-oxo-2,1-ethanediyl))) dimethyl biscarbamate, vhc inhibitors; intermediary compounds; pharmaceutical composition; pharmaceutical combination; and use to treat a vhc infection.
IN2015DN02907A (en)
PH12012502171A1 (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
MX2009007784A (en) Compositions of stable tiacumicins.
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.
EA201290985A1 (en) ORAL VETERINARY PHARMACEUTICAL AND NUTRITSEVTIC COMPOSITIONS
SV2011003852A (en) INHALABLE PARTICLES THAT INCLUDE TIOTROPIO
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
EA201200604A1 (en) PHARMACEUTICAL SUBSTANCES ON THE BASIS OF MITOCHONDRIAL ADDRESSED ANTIOXIDANTS
MX356105B (en) Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4 -methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-i soindol-4-yl}-amidecelgene corporation state of incorporation:delaware.
CO6341474A2 (en) SOLID FORMS OF (1R, 2S, 3R) -1- (2-ISOXAZOL-3-IL) -1H-IMIDAZOL-4-IL) BUTANE-1,2,3,4-TETRAOL AND METHODS FOR USE
EA201691034A1 (en) COMPOSITIONS IN SOLID SHORT-DOWN SHIPPING FOR ORAL ADMISSION

Legal Events

Date Code Title Description
FC Application refused